 Michael Narkewicz
Concepts (600)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Diseases | 24 | 2024 | 284 | 5.280 |
Why?
| | Cystic Fibrosis | 32 | 2024 | 1061 | 5.270 |
Why?
| | Liver Cirrhosis | 18 | 2023 | 274 | 3.280 |
Why?
| | Elasticity Imaging Techniques | 7 | 2024 | 48 | 3.010 |
Why?
| | Liver | 38 | 2023 | 1832 | 2.430 |
Why?
| | Hepatitis C, Chronic | 18 | 2024 | 154 | 2.260 |
Why?
| | Liver Failure, Acute | 13 | 2018 | 62 | 2.250 |
Why?
| | Hypertension, Portal | 9 | 2023 | 61 | 2.000 |
Why?
| | Liver Transplantation | 27 | 2023 | 800 | 1.740 |
Why?
| | Antiviral Agents | 17 | 2024 | 708 | 1.420 |
Why?
| | Gastroenterology | 7 | 2024 | 177 | 1.350 |
Why?
| | Interferon-alpha | 13 | 2013 | 191 | 1.240 |
Why?
| | Child | 89 | 2024 | 20824 | 1.070 |
Why?
| | Biliary Atresia | 9 | 2015 | 160 | 1.060 |
Why?
| | Child, Preschool | 66 | 2024 | 10457 | 0.930 |
Why?
| | Serine | 7 | 2002 | 133 | 0.830 |
Why?
| | Fontan Procedure | 3 | 2018 | 169 | 0.810 |
Why?
| | Pancreatitis | 3 | 2020 | 129 | 0.790 |
Why?
| | Lymphoproliferative Disorders | 3 | 2013 | 53 | 0.780 |
Why?
| | Ribavirin | 8 | 2020 | 92 | 0.780 |
Why?
| | Epstein-Barr Virus Infections | 4 | 2013 | 93 | 0.770 |
Why?
| | Esophageal Stenosis | 2 | 2018 | 51 | 0.740 |
Why?
| | Ursodeoxycholic Acid | 3 | 2016 | 19 | 0.710 |
Why?
| | Alanine Transaminase | 6 | 2016 | 147 | 0.710 |
Why?
| | gamma-Glutamyltransferase | 5 | 2016 | 40 | 0.710 |
Why?
| | Pancreatitis, Chronic | 2 | 2020 | 51 | 0.680 |
Why?
| | Humans | 128 | 2024 | 128896 | 0.650 |
Why?
| | Liver Function Tests | 7 | 2016 | 110 | 0.650 |
Why?
| | Aspartate Aminotransferases | 3 | 2016 | 86 | 0.640 |
Why?
| | Cholestasis | 7 | 2022 | 229 | 0.640 |
Why?
| | Bile Ducts | 3 | 2013 | 66 | 0.620 |
Why?
| | Infant | 46 | 2019 | 8994 | 0.600 |
Why?
| | Adolescent | 59 | 2024 | 20197 | 0.600 |
Why?
| | Postoperative Complications | 7 | 2018 | 2494 | 0.600 |
Why?
| | Platelet Count | 3 | 2024 | 83 | 0.590 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 6 | 2023 | 316 | 0.590 |
Why?
| | Feces | 3 | 2024 | 430 | 0.580 |
Why?
| | Esophageal and Gastric Varices | 5 | 2022 | 35 | 0.580 |
Why?
| | Hepacivirus | 8 | 2024 | 235 | 0.580 |
Why?
| | Disease Management | 2 | 2018 | 594 | 0.550 |
Why?
| | Hepatitis, Autoimmune | 1 | 2017 | 20 | 0.550 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 101 | 0.550 |
Why?
| | Female | 92 | 2024 | 68162 | 0.540 |
Why?
| | Male | 79 | 2024 | 63146 | 0.510 |
Why?
| | Benzimidazoles | 4 | 2024 | 158 | 0.510 |
Why?
| | Glycine | 6 | 2002 | 162 | 0.500 |
Why?
| | Liver Failure | 3 | 2013 | 90 | 0.490 |
Why?
| | Pediatrics | 5 | 2020 | 1060 | 0.490 |
Why?
| | Physical Examination | 2 | 2018 | 237 | 0.460 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2016 | 215 | 0.450 |
Why?
| | Gastrointestinal Hemorrhage | 6 | 2022 | 117 | 0.420 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2013 | 18 | 0.420 |
Why?
| | Infant, Newborn | 18 | 2018 | 5704 | 0.410 |
Why?
| | Gastrointestinal Microbiome | 2 | 2024 | 635 | 0.410 |
Why?
| | Prospective Studies | 16 | 2023 | 7060 | 0.410 |
Why?
| | Educational Measurement | 1 | 2015 | 259 | 0.410 |
Why?
| | Colonoscopy | 1 | 2015 | 225 | 0.400 |
Why?
| | Hepatitis B, Chronic | 3 | 2010 | 18 | 0.400 |
Why?
| | Acetamides | 1 | 2013 | 37 | 0.400 |
Why?
| | Autoantibodies | 3 | 2017 | 1460 | 0.400 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 752 | 0.390 |
Why?
| | Carbamates | 2 | 2024 | 45 | 0.390 |
Why?
| | Mutation | 4 | 2023 | 3671 | 0.390 |
Why?
| | Sheep | 8 | 2002 | 832 | 0.390 |
Why?
| | Drug Combinations | 5 | 2024 | 327 | 0.390 |
Why?
| | Carbon Dioxide | 2 | 2013 | 261 | 0.370 |
Why?
| | Cohort Studies | 12 | 2023 | 5394 | 0.360 |
Why?
| | Folic Acid | 2 | 2002 | 182 | 0.350 |
Why?
| | Ultrasonography | 5 | 2020 | 727 | 0.340 |
Why?
| | Blindness | 1 | 2010 | 38 | 0.340 |
Why?
| | Polyethylene Glycols | 9 | 2013 | 598 | 0.340 |
Why?
| | Clinical Competence | 3 | 2020 | 1020 | 0.340 |
Why?
| | Prognosis | 15 | 2020 | 3787 | 0.340 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 569 | 0.330 |
Why?
| | Retinal Diseases | 1 | 2010 | 86 | 0.330 |
Why?
| | Uridine Monophosphate | 2 | 2019 | 15 | 0.320 |
Why?
| | Uveitis | 1 | 2010 | 128 | 0.320 |
Why?
| | Optic Neuritis | 1 | 2009 | 38 | 0.320 |
Why?
| | Fluorenes | 2 | 2019 | 39 | 0.310 |
Why?
| | Chloride Channel Agonists | 4 | 2024 | 73 | 0.310 |
Why?
| | Esophagoscopy | 3 | 2018 | 196 | 0.310 |
Why?
| | Research | 2 | 2002 | 413 | 0.310 |
Why?
| | Benzodioxoles | 3 | 2024 | 102 | 0.300 |
Why?
| | Sofosbuvir | 3 | 2024 | 57 | 0.300 |
Why?
| | Hepatitis C | 4 | 2012 | 234 | 0.290 |
Why?
| | Recombinant Proteins | 12 | 2013 | 1304 | 0.290 |
Why?
| | ROC Curve | 3 | 2019 | 500 | 0.290 |
Why?
| | Prevalence | 5 | 2017 | 2540 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2270 | 0.290 |
Why?
| | Pyrrolidines | 3 | 2024 | 65 | 0.280 |
Why?
| | Aminophenols | 3 | 2024 | 141 | 0.280 |
Why?
| | Glycine Hydroxymethyltransferase | 4 | 2001 | 16 | 0.280 |
Why?
| | Biomarkers | 11 | 2022 | 3874 | 0.280 |
Why?
| | Severity of Illness Index | 10 | 2020 | 2767 | 0.270 |
Why?
| | Sulfonamides | 2 | 2021 | 494 | 0.270 |
Why?
| | Canada | 4 | 2018 | 355 | 0.260 |
Why?
| | Immediate-Early Proteins | 1 | 2005 | 58 | 0.250 |
Why?
| | Cholestasis, Intrahepatic | 3 | 2003 | 38 | 0.250 |
Why?
| | Galactose | 2 | 2003 | 25 | 0.250 |
Why?
| | Quinolones | 2 | 2024 | 123 | 0.240 |
Why?
| | Biliary Tract Diseases | 2 | 2002 | 36 | 0.240 |
Why?
| | Alagille Syndrome | 2 | 2022 | 33 | 0.230 |
Why?
| | Quality of Health Care | 1 | 2009 | 610 | 0.230 |
Why?
| | Treatment Outcome | 20 | 2024 | 10239 | 0.230 |
Why?
| | Transfusion Reaction | 1 | 2004 | 41 | 0.230 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 19 | 0.230 |
Why?
| | Lung Diseases | 2 | 2018 | 755 | 0.230 |
Why?
| | Mass Screening | 2 | 2023 | 1121 | 0.220 |
Why?
| | Retrospective Studies | 17 | 2018 | 14546 | 0.220 |
Why?
| | Indoles | 2 | 2024 | 378 | 0.220 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 376 | 0.220 |
Why?
| | Ascites | 2 | 2015 | 41 | 0.220 |
Why?
| | Case-Control Studies | 8 | 2020 | 3334 | 0.210 |
Why?
| | Follow-Up Studies | 10 | 2022 | 4917 | 0.210 |
Why?
| | Disease Progression | 5 | 2020 | 2603 | 0.210 |
Why?
| | Platelet Activation | 1 | 2003 | 85 | 0.210 |
Why?
| | Placenta | 4 | 2010 | 706 | 0.200 |
Why?
| | Young Adult | 10 | 2024 | 12286 | 0.200 |
Why?
| | Bilirubin | 5 | 2015 | 91 | 0.190 |
Why?
| | Paracentesis | 1 | 2001 | 11 | 0.190 |
Why?
| | Choledochal Cyst | 3 | 2013 | 16 | 0.190 |
Why?
| | Registries | 5 | 2018 | 1916 | 0.190 |
Why?
| | Hepatocytes | 1 | 2002 | 215 | 0.190 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 2 | 2006 | 204 | 0.180 |
Why?
| | United States | 8 | 2020 | 13975 | 0.180 |
Why?
| | Herpesvirus 4, Human | 3 | 2013 | 153 | 0.180 |
Why?
| | Portoenterostomy, Hepatic | 4 | 2015 | 45 | 0.180 |
Why?
| | Quinoxalines | 1 | 2021 | 64 | 0.180 |
Why?
| | Menstruation | 1 | 2020 | 43 | 0.180 |
Why?
| | Risk Factors | 10 | 2018 | 9792 | 0.180 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 460 | 0.180 |
Why?
| | Uracil | 1 | 2020 | 29 | 0.170 |
Why?
| | Consensus | 1 | 2023 | 644 | 0.170 |
Why?
| | Cyclopropanes | 1 | 2020 | 88 | 0.170 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 20 | 0.170 |
Why?
| | Acute Disease | 3 | 2016 | 978 | 0.170 |
Why?
| | Lactams, Macrocyclic | 1 | 2020 | 49 | 0.170 |
Why?
| | Anilides | 1 | 2020 | 72 | 0.170 |
Why?
| | Postoperative Care | 2 | 2019 | 246 | 0.170 |
Why?
| | Bile Acids and Salts | 2 | 2016 | 194 | 0.170 |
Why?
| | Ritonavir | 1 | 2020 | 72 | 0.170 |
Why?
| | Proline | 1 | 2020 | 79 | 0.160 |
Why?
| | Drug Therapy, Combination | 7 | 2020 | 1020 | 0.160 |
Why?
| | Databases, Factual | 4 | 2015 | 1289 | 0.160 |
Why?
| | Hepatic Encephalopathy | 5 | 2013 | 19 | 0.160 |
Why?
| | Hepatitis, Chronic | 2 | 1995 | 5 | 0.160 |
Why?
| | Adult | 23 | 2024 | 35361 | 0.160 |
Why?
| | Carrier Proteins | 3 | 2016 | 728 | 0.160 |
Why?
| | Biopsy | 8 | 2019 | 1093 | 0.160 |
Why?
| | Neonatal Screening | 3 | 2016 | 161 | 0.160 |
Why?
| | Phosphoenolpyruvate Carboxykinase (GTP) | 4 | 1993 | 31 | 0.160 |
Why?
| | Common Bile Duct Diseases | 1 | 1998 | 3 | 0.150 |
Why?
| | Electrocoagulation | 1 | 2018 | 37 | 0.150 |
Why?
| | Longitudinal Studies | 4 | 2019 | 2668 | 0.150 |
Why?
| | Dilatation | 1 | 2018 | 62 | 0.150 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 197 | 0.150 |
Why?
| | Exercise Test | 2 | 2018 | 619 | 0.150 |
Why?
| | Epidermolysis Bullosa | 1 | 2018 | 59 | 0.150 |
Why?
| | Pyruvic Acid | 2 | 2017 | 52 | 0.150 |
Why?
| | Fluoroscopy | 1 | 2018 | 167 | 0.150 |
Why?
| | Age Factors | 4 | 2017 | 3133 | 0.150 |
Why?
| | Survival Rate | 8 | 2019 | 1884 | 0.140 |
Why?
| | Logistic Models | 3 | 2017 | 1963 | 0.140 |
Why?
| | Graft Rejection | 2 | 2013 | 566 | 0.140 |
Why?
| | Sustained Virologic Response | 3 | 2024 | 35 | 0.140 |
Why?
| | Trypsin Inhibitor, Kazal Pancreatic | 1 | 2016 | 5 | 0.130 |
Why?
| | Trypsin | 1 | 2016 | 73 | 0.130 |
Why?
| | Autoimmune Diseases | 3 | 2013 | 419 | 0.130 |
Why?
| | Lactic Acid | 2 | 2017 | 296 | 0.130 |
Why?
| | Lung Transplantation | 1 | 2019 | 276 | 0.130 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 89 | 0.130 |
Why?
| | Growth Disorders | 2 | 2015 | 78 | 0.130 |
Why?
| | Fetus | 3 | 2000 | 764 | 0.130 |
Why?
| | Preoperative Care | 2 | 2019 | 343 | 0.130 |
Why?
| | Kidney | 2 | 2001 | 1330 | 0.130 |
Why?
| | Recurrence | 3 | 2016 | 1013 | 0.130 |
Why?
| | Zinc | 1 | 1999 | 291 | 0.130 |
Why?
| | Fatty Liver | 2 | 2012 | 230 | 0.120 |
Why?
| | Parenteral Nutrition, Total | 1 | 1995 | 27 | 0.120 |
Why?
| | Statistics as Topic | 1 | 2016 | 306 | 0.120 |
Why?
| | Cells, Cultured | 8 | 2015 | 4048 | 0.120 |
Why?
| | Capsule Endoscopes | 1 | 2015 | 7 | 0.120 |
Why?
| | Incidence | 3 | 2018 | 2634 | 0.120 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2015 | 29 | 0.120 |
Why?
| | RNA, Messenger | 5 | 2005 | 2700 | 0.120 |
Why?
| | Hepatitis B | 1 | 1995 | 61 | 0.120 |
Why?
| | Quality of Life | 4 | 2022 | 2706 | 0.120 |
Why?
| | Glucokinase | 3 | 1991 | 13 | 0.120 |
Why?
| | Sensitivity and Specificity | 2 | 2018 | 1840 | 0.120 |
Why?
| | Permeability | 1 | 2015 | 158 | 0.120 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 217 | 0.110 |
Why?
| | Prothrombin Time | 4 | 2012 | 33 | 0.110 |
Why?
| | Cross-Sectional Studies | 4 | 2018 | 5032 | 0.110 |
Why?
| | Animals, Newborn | 2 | 2001 | 813 | 0.110 |
Why?
| | Cysteine | 1 | 1995 | 190 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 861 | 0.110 |
Why?
| | Curriculum | 1 | 2020 | 925 | 0.110 |
Why?
| | Amino Acids | 2 | 1996 | 469 | 0.110 |
Why?
| | Insulin-Like Growth Factor II | 1 | 1993 | 25 | 0.110 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 65 | 0.110 |
Why?
| | Hepatitis, Viral, Human | 2 | 2006 | 25 | 0.110 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 76 | 0.100 |
Why?
| | Lymphocyte Activation | 2 | 2015 | 1091 | 0.100 |
Why?
| | Cognition | 2 | 2011 | 1093 | 0.100 |
Why?
| | Decision Making | 1 | 2019 | 837 | 0.100 |
Why?
| | Risk Assessment | 4 | 2020 | 3286 | 0.100 |
Why?
| | Chronic Disease | 6 | 2010 | 1715 | 0.100 |
Why?
| | Professional Competence | 1 | 2013 | 94 | 0.100 |
Why?
| | Acetylcysteine | 1 | 2013 | 148 | 0.100 |
Why?
| | Lipid Metabolism | 1 | 1995 | 491 | 0.100 |
Why?
| | DNA, Viral | 4 | 2010 | 380 | 0.100 |
Why?
| | Glucose | 4 | 2002 | 976 | 0.100 |
Why?
| | Algorithms | 1 | 2019 | 1626 | 0.100 |
Why?
| | Time Factors | 11 | 2019 | 6568 | 0.100 |
Why?
| | Diffuse Cerebral Sclerosis of Schilder | 1 | 1991 | 4 | 0.100 |
Why?
| | United Kingdom | 2 | 2009 | 263 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1040 | 0.090 |
Why?
| | Pregnancy | 9 | 2010 | 6247 | 0.090 |
Why?
| | Animals | 18 | 2002 | 34628 | 0.090 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1993 | 308 | 0.090 |
Why?
| | Triiodothyronine | 1 | 1990 | 44 | 0.090 |
Why?
| | Behavior | 1 | 2011 | 92 | 0.090 |
Why?
| | Embryonic and Fetal Development | 2 | 2001 | 95 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2018 | 966 | 0.090 |
Why?
| | Lauric Acids | 1 | 2010 | 4 | 0.090 |
Why?
| | Internship and Residency | 1 | 2020 | 1052 | 0.090 |
Why?
| | Clinical Chemistry Tests | 1 | 2010 | 10 | 0.090 |
Why?
| | Malabsorption Syndromes | 1 | 2010 | 16 | 0.090 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2010 | 52 | 0.090 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3042 | 0.080 |
Why?
| | Vitamin A Deficiency | 2 | 2005 | 27 | 0.080 |
Why?
| | Fetal Blood | 2 | 2010 | 315 | 0.080 |
Why?
| | Natriuretic Peptides | 1 | 2009 | 9 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2015 | 824 | 0.080 |
Why?
| | Suture Techniques | 1 | 2010 | 120 | 0.080 |
Why?
| | Digestive System Surgical Procedures | 1 | 2010 | 96 | 0.080 |
Why?
| | Up-Regulation | 1 | 2013 | 848 | 0.080 |
Why?
| | Enzymes | 1 | 2010 | 65 | 0.080 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2009 | 23 | 0.080 |
Why?
| | Pyrazoles | 2 | 2024 | 403 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1504 | 0.080 |
Why?
| | Pyridines | 2 | 2024 | 472 | 0.080 |
Why?
| | Genotype | 3 | 2024 | 1834 | 0.080 |
Why?
| | Optic Nerve | 1 | 2009 | 65 | 0.080 |
Why?
| | Roseolovirus Infections | 1 | 2009 | 7 | 0.080 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2009 | 14 | 0.080 |
Why?
| | Protozoan Infections | 1 | 1989 | 10 | 0.080 |
Why?
| | Amino Acid Oxidoreductases | 2 | 2001 | 19 | 0.080 |
Why?
| | Hospitalization | 2 | 2016 | 2080 | 0.080 |
Why?
| | Transferases | 2 | 2001 | 33 | 0.080 |
Why?
| | Interferon-gamma | 2 | 2015 | 759 | 0.080 |
Why?
| | Agammaglobulinemia | 1 | 2009 | 34 | 0.080 |
Why?
| | Multienzyme Complexes | 2 | 2001 | 69 | 0.080 |
Why?
| | Vitamin E | 6 | 2005 | 118 | 0.080 |
Why?
| | Biliary Tract Surgical Procedures | 2 | 2011 | 25 | 0.080 |
Why?
| | Body Composition | 1 | 2012 | 654 | 0.070 |
Why?
| | Dietary Fats | 1 | 2010 | 302 | 0.070 |
Why?
| | Societies, Medical | 3 | 2013 | 760 | 0.070 |
Why?
| | Gastroenteritis | 1 | 1989 | 66 | 0.070 |
Why?
| | Lung | 2 | 2012 | 3925 | 0.070 |
Why?
| | Hemophilia A | 1 | 1989 | 75 | 0.070 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1989 | 226 | 0.070 |
Why?
| | Ischemia | 1 | 2010 | 396 | 0.070 |
Why?
| | Fatty Acids | 1 | 2010 | 415 | 0.070 |
Why?
| | Abdomen, Acute | 1 | 2006 | 18 | 0.070 |
Why?
| | Survival Analysis | 5 | 2013 | 1282 | 0.070 |
Why?
| | Bile Duct Diseases | 1 | 2006 | 14 | 0.070 |
Why?
| | Vitamin A | 2 | 2005 | 55 | 0.070 |
Why?
| | Child Behavior | 1 | 2009 | 235 | 0.070 |
Why?
| | Research Design | 1 | 2012 | 1038 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2006 | 118 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2009 | 1876 | 0.060 |
Why?
| | Laparoscopy | 1 | 2010 | 452 | 0.060 |
Why?
| | Biliary Tract | 1 | 2005 | 15 | 0.060 |
Why?
| | Emotions | 1 | 2011 | 536 | 0.060 |
Why?
| | Connective Tissue Growth Factor | 1 | 2005 | 24 | 0.060 |
Why?
| | Influenza A virus | 1 | 2006 | 104 | 0.060 |
Why?
| | Copper | 2 | 1998 | 108 | 0.060 |
Why?
| | Autopsy | 1 | 2005 | 89 | 0.060 |
Why?
| | Glycogen Storage Disease Type IV | 1 | 2005 | 4 | 0.060 |
Why?
| | 1,4-alpha-Glucan Branching Enzyme | 1 | 2005 | 4 | 0.060 |
Why?
| | Bile | 1 | 2005 | 27 | 0.060 |
Why?
| | In Situ Hybridization | 1 | 2005 | 295 | 0.060 |
Why?
| | Insulin | 4 | 1993 | 2311 | 0.060 |
Why?
| | Culture Media | 3 | 1996 | 168 | 0.060 |
Why?
| | Predictive Value of Tests | 4 | 2013 | 1967 | 0.060 |
Why?
| | Endoscopy | 2 | 1998 | 268 | 0.060 |
Why?
| | Carnitine | 1 | 2005 | 75 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1905 | 0.060 |
Why?
| | Acetyl-CoA Carboxylase | 3 | 1995 | 33 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2010 | 802 | 0.060 |
Why?
| | Drug Resistance, Viral | 2 | 2018 | 110 | 0.060 |
Why?
| | Glucagon | 3 | 2002 | 105 | 0.060 |
Why?
| | Benzopyrans | 1 | 2024 | 31 | 0.060 |
Why?
| | Mothers | 1 | 2010 | 723 | 0.060 |
Why?
| | Disease Transmission, Infectious | 1 | 2004 | 56 | 0.060 |
Why?
| | Lupus Erythematosus, Cutaneous | 1 | 2003 | 8 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 2018 | 596 | 0.050 |
Why?
| | Kinetics | 3 | 2000 | 1619 | 0.050 |
Why?
| | Platelet Factor 4 | 1 | 2003 | 33 | 0.050 |
Why?
| | Blood Donors | 1 | 2004 | 94 | 0.050 |
Why?
| | Blood Coagulation Tests | 1 | 2003 | 54 | 0.050 |
Why?
| | Endoglin | 1 | 2022 | 19 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 201 | 0.050 |
Why?
| | Carbon Radioisotopes | 2 | 2000 | 35 | 0.050 |
Why?
| | Anastomosis, Surgical | 2 | 2011 | 149 | 0.050 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2004 | 166 | 0.050 |
Why?
| | Pancreatic Elastase | 1 | 2022 | 60 | 0.050 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 24 | 0.050 |
Why?
| | Niemann-Pick Diseases | 1 | 2002 | 2 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2002 | 77 | 0.050 |
Why?
| | Pilot Projects | 4 | 2006 | 1545 | 0.050 |
Why?
| | Analysis of Variance | 2 | 2015 | 1283 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 1701 | 0.050 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2003 | 162 | 0.050 |
Why?
| | Dysbiosis | 1 | 2024 | 166 | 0.050 |
Why?
| | International Normalized Ratio | 2 | 2012 | 47 | 0.050 |
Why?
| | Enzyme Induction | 2 | 1993 | 90 | 0.050 |
Why?
| | Umbilical Veins | 1 | 2002 | 61 | 0.050 |
Why?
| | Somatostatin | 1 | 2002 | 55 | 0.050 |
Why?
| | Plasma Volume | 1 | 2001 | 18 | 0.050 |
Why?
| | Punctures | 1 | 2001 | 40 | 0.050 |
Why?
| | Cholangitis | 1 | 2001 | 20 | 0.050 |
Why?
| | Weaning | 4 | 1995 | 49 | 0.050 |
Why?
| | Constipation | 1 | 2022 | 89 | 0.050 |
Why?
| | Patient Selection | 2 | 2019 | 671 | 0.050 |
Why?
| | Interleukin-8 | 1 | 2022 | 261 | 0.050 |
Why?
| | Oxidoreductases Acting on CH-NH Group Donors | 1 | 2001 | 2 | 0.050 |
Why?
| | Caregivers | 1 | 2009 | 821 | 0.050 |
Why?
| | 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2001 | 16 | 0.050 |
Why?
| | Health Status | 2 | 2022 | 750 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1694 | 0.050 |
Why?
| | Genotyping Techniques | 1 | 2021 | 72 | 0.050 |
Why?
| | Tetrahydrofolates | 1 | 2001 | 18 | 0.050 |
Why?
| | Cardiomyopathies | 1 | 2005 | 333 | 0.050 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2002 | 105 | 0.050 |
Why?
| | RNA, Viral | 2 | 2010 | 622 | 0.050 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2001 | 35 | 0.050 |
Why?
| | Needles | 1 | 2001 | 57 | 0.050 |
Why?
| | Leucovorin | 1 | 2001 | 69 | 0.050 |
Why?
| | Chlorides | 1 | 2022 | 138 | 0.050 |
Why?
| | North America | 1 | 2002 | 289 | 0.040 |
Why?
| | Stress, Psychological | 1 | 2009 | 1051 | 0.040 |
Why?
| | Catheterization | 1 | 2001 | 176 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2003 | 642 | 0.040 |
Why?
| | Drainage | 1 | 2001 | 162 | 0.040 |
Why?
| | 2-Naphthylamine | 1 | 2020 | 7 | 0.040 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2020 | 13 | 0.040 |
Why?
| | Intestinal Absorption | 2 | 2010 | 98 | 0.040 |
Why?
| | Tablets | 1 | 2020 | 39 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 108 | 0.040 |
Why?
| | Influenza, Human | 1 | 2006 | 603 | 0.040 |
Why?
| | Gestational Age | 2 | 2002 | 857 | 0.040 |
Why?
| | Nutritional Status | 2 | 2015 | 325 | 0.040 |
Why?
| | Accreditation | 1 | 2020 | 81 | 0.040 |
Why?
| | Blood Platelets | 1 | 2003 | 369 | 0.040 |
Why?
| | Phosphoglycerate Dehydrogenase | 1 | 1999 | 4 | 0.040 |
Why?
| | Hepatitis B virus | 2 | 2010 | 34 | 0.040 |
Why?
| | Carbohydrate Dehydrogenases | 1 | 1999 | 11 | 0.040 |
Why?
| | Valine | 1 | 2020 | 78 | 0.040 |
Why?
| | Animals, Suckling | 3 | 1995 | 9 | 0.040 |
Why?
| | Transaminases | 1 | 1999 | 23 | 0.040 |
Why?
| | Binding, Competitive | 1 | 2000 | 208 | 0.040 |
Why?
| | Rabbits | 1 | 2001 | 757 | 0.040 |
Why?
| | Lipids | 4 | 2002 | 614 | 0.040 |
Why?
| | Competency-Based Education | 1 | 2020 | 70 | 0.040 |
Why?
| | Syndrome | 2 | 2009 | 342 | 0.040 |
Why?
| | Rats | 6 | 1995 | 5236 | 0.040 |
Why?
| | Referral and Consultation | 2 | 2019 | 727 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2023 | 859 | 0.040 |
Why?
| | Leucine | 1 | 2000 | 106 | 0.040 |
Why?
| | Safety | 1 | 2001 | 325 | 0.040 |
Why?
| | Pruritus | 1 | 1999 | 62 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2005 | 1059 | 0.040 |
Why?
| | Rifampin | 1 | 1999 | 82 | 0.040 |
Why?
| | Hypersplenism | 1 | 1998 | 7 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 1991 | 289 | 0.040 |
Why?
| | Heart | 1 | 2003 | 650 | 0.040 |
Why?
| | Isoenzymes | 1 | 1999 | 303 | 0.040 |
Why?
| | Biological Transport | 1 | 2000 | 394 | 0.040 |
Why?
| | Diagnostic Imaging | 1 | 2001 | 327 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1694 | 0.040 |
Why?
| | Duodenoscopy | 1 | 1998 | 7 | 0.040 |
Why?
| | Medicine | 1 | 2020 | 118 | 0.040 |
Why?
| | Pemoline | 1 | 1998 | 5 | 0.040 |
Why?
| | Gluconeogenesis | 2 | 2002 | 73 | 0.040 |
Why?
| | Sphincterotomy, Endoscopic | 1 | 1998 | 26 | 0.040 |
Why?
| | Rats, Inbred Strains | 4 | 1990 | 365 | 0.040 |
Why?
| | Genes, Viral | 1 | 1998 | 94 | 0.040 |
Why?
| | Gallstones | 1 | 1998 | 30 | 0.040 |
Why?
| | Reoviridae | 1 | 1998 | 37 | 0.040 |
Why?
| | Serum Albumin | 1 | 1999 | 145 | 0.040 |
Why?
| | Technetium Tc 99m Disofenin | 1 | 1998 | 3 | 0.040 |
Why?
| | Age Distribution | 1 | 2019 | 376 | 0.040 |
Why?
| | Postoperative Period | 1 | 1999 | 319 | 0.040 |
Why?
| | Reoviridae Infections | 1 | 1998 | 53 | 0.040 |
Why?
| | Medical History Taking | 1 | 2018 | 119 | 0.040 |
Why?
| | Half-Life | 1 | 1998 | 148 | 0.040 |
Why?
| | Hemodynamics | 1 | 2003 | 1095 | 0.040 |
Why?
| | Pancreatic Diseases | 1 | 1998 | 67 | 0.040 |
Why?
| | Manganese | 1 | 1998 | 61 | 0.040 |
Why?
| | Caffeine | 1 | 1998 | 62 | 0.040 |
Why?
| | Pancreas Transplantation | 1 | 2017 | 74 | 0.040 |
Why?
| | Reference Values | 1 | 1999 | 791 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 182 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 62 | 0.030 |
Why?
| | Creatinine | 1 | 1999 | 485 | 0.030 |
Why?
| | Fellowships and Scholarships | 1 | 2020 | 271 | 0.030 |
Why?
| | Ammonia | 2 | 2008 | 62 | 0.030 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1998 | 136 | 0.030 |
Why?
| | Central Nervous System Stimulants | 1 | 1998 | 153 | 0.030 |
Why?
| | Injections, Subcutaneous | 2 | 2006 | 145 | 0.030 |
Why?
| | Esophagus | 1 | 2018 | 253 | 0.030 |
Why?
| | Embolization, Therapeutic | 1 | 1998 | 209 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2010 | 760 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 436 | 0.030 |
Why?
| | Hypoalbuminemia | 1 | 2015 | 29 | 0.030 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2015 | 31 | 0.030 |
Why?
| | CHO Cells | 1 | 1996 | 146 | 0.030 |
Why?
| | Cricetinae | 1 | 1996 | 275 | 0.030 |
Why?
| | Body Mass Index | 2 | 2015 | 2244 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 1998 | 513 | 0.030 |
Why?
| | Food, Fortified | 1 | 1995 | 37 | 0.030 |
Why?
| | Cytosol | 1 | 1996 | 210 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2015 | 95 | 0.030 |
Why?
| | Radiography | 1 | 1998 | 863 | 0.030 |
Why?
| | Solubility | 2 | 2013 | 233 | 0.030 |
Why?
| | Glycerol | 1 | 1995 | 87 | 0.030 |
Why?
| | Transcription, Genetic | 2 | 1999 | 1408 | 0.030 |
Why?
| | Hepatolenticular Degeneration | 1 | 1994 | 15 | 0.030 |
Why?
| | Brain | 2 | 2001 | 2592 | 0.030 |
Why?
| | Immunosuppressive Agents | 3 | 2007 | 699 | 0.030 |
Why?
| | Remission Induction | 1 | 1995 | 269 | 0.030 |
Why?
| | Ileum | 1 | 1995 | 113 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 1995 | 424 | 0.030 |
Why?
| | Inflammation | 1 | 2005 | 2694 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2015 | 213 | 0.030 |
Why?
| | Echocardiography | 2 | 2009 | 634 | 0.030 |
Why?
| | Mitochondria, Liver | 1 | 1994 | 73 | 0.030 |
Why?
| | Random Allocation | 1 | 1995 | 351 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1221 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 427 | 0.030 |
Why?
| | Oxidants | 1 | 1994 | 109 | 0.030 |
Why?
| | Lipid Peroxidation | 2 | 1994 | 147 | 0.030 |
Why?
| | Choline | 1 | 1995 | 117 | 0.030 |
Why?
| | Cyclosporine | 1 | 1994 | 172 | 0.030 |
Why?
| | Vitamin E Deficiency | 2 | 1991 | 43 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2013 | 61 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 225 | 0.030 |
Why?
| | Prednisone | 1 | 1994 | 241 | 0.030 |
Why?
| | Thymidine | 1 | 1993 | 58 | 0.030 |
Why?
| | Lactates | 1 | 1993 | 83 | 0.030 |
Why?
| | Colon | 1 | 1995 | 246 | 0.030 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 11 | 0.030 |
Why?
| | Fatty Acid Synthases | 2 | 1990 | 24 | 0.030 |
Why?
| | Free Radical Scavengers | 1 | 2013 | 81 | 0.030 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 27 | 0.030 |
Why?
| | Polymerase Chain Reaction | 3 | 2002 | 1045 | 0.030 |
Why?
| | Pseudomonas aeruginosa | 1 | 2015 | 343 | 0.030 |
Why?
| | Eating | 2 | 2012 | 366 | 0.020 |
Why?
| | Aging | 2 | 2001 | 1767 | 0.020 |
Why?
| | Signal Transduction | 1 | 2005 | 4857 | 0.020 |
Why?
| | Cell Separation | 1 | 1993 | 311 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2013 | 395 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1146 | 0.020 |
Why?
| | Vitamins | 2 | 1991 | 171 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2013 | 310 | 0.020 |
Why?
| | Cyclosporins | 1 | 1991 | 59 | 0.020 |
Why?
| | Hyperbilirubinemia | 1 | 2011 | 11 | 0.020 |
Why?
| | Hemochromatosis | 1 | 2011 | 8 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3348 | 0.020 |
Why?
| | Cell Division | 1 | 1993 | 800 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 191 | 0.020 |
Why?
| | Vital Capacity | 1 | 2012 | 285 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1281 | 0.020 |
Why?
| | Choledochostomy | 1 | 2011 | 11 | 0.020 |
Why?
| | Status Epilepticus | 1 | 1991 | 42 | 0.020 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2011 | 27 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1523 | 0.020 |
Why?
| | Stimulation, Chemical | 1 | 1990 | 62 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 1947 | 0.020 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2010 | 19 | 0.020 |
Why?
| | Decidua | 1 | 2010 | 23 | 0.020 |
Why?
| | Prader-Willi Syndrome | 1 | 2010 | 27 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2012 | 509 | 0.020 |
Why?
| | Rectal Prolapse | 1 | 2010 | 21 | 0.020 |
Why?
| | Risk | 2 | 2005 | 866 | 0.020 |
Why?
| | Lamivudine | 1 | 2010 | 61 | 0.020 |
Why?
| | Enzyme Therapy | 1 | 2010 | 4 | 0.020 |
Why?
| | Herpes Simplex | 1 | 2011 | 94 | 0.020 |
Why?
| | Ligases | 1 | 1990 | 31 | 0.020 |
Why?
| | Organophosphonates | 1 | 2010 | 91 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5355 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 135 | 0.020 |
Why?
| | Natural Killer T-Cells | 1 | 2010 | 64 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2308 | 0.020 |
Why?
| | Mitochondria | 1 | 1996 | 837 | 0.020 |
Why?
| | Killer Cells, Natural | 1 | 2013 | 422 | 0.020 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 49 | 0.020 |
Why?
| | Legal Guardians | 1 | 2009 | 9 | 0.020 |
Why?
| | Rectum | 1 | 2010 | 166 | 0.020 |
Why?
| | Herpesvirus 7, Human | 1 | 2009 | 6 | 0.020 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2010 | 172 | 0.020 |
Why?
| | Hormones | 1 | 1990 | 139 | 0.020 |
Why?
| | Sickness Impact Profile | 1 | 2009 | 54 | 0.020 |
Why?
| | Opportunistic Infections | 1 | 1989 | 46 | 0.020 |
Why?
| | Vitamin D Deficiency | 1 | 1991 | 179 | 0.020 |
Why?
| | Adenine | 1 | 2010 | 247 | 0.020 |
Why?
| | Living Donors | 1 | 2011 | 298 | 0.020 |
Why?
| | Hypoglycemia | 1 | 1993 | 427 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1858 | 0.020 |
Why?
| | Gene Expression | 1 | 1993 | 1476 | 0.020 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2009 | 131 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 931 | 0.020 |
Why?
| | Middle Aged | 5 | 2019 | 30977 | 0.020 |
Why?
| | Pancreas | 1 | 2010 | 307 | 0.020 |
Why?
| | Rupture, Spontaneous | 1 | 2006 | 20 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2010 | 478 | 0.020 |
Why?
| | Fibrosis | 1 | 2009 | 518 | 0.020 |
Why?
| | Probability | 1 | 2007 | 313 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1002 | 0.020 |
Why?
| | Treatment Failure | 1 | 2007 | 345 | 0.020 |
Why?
| | Interferon-beta | 1 | 2006 | 88 | 0.020 |
Why?
| | DNA | 1 | 1993 | 1406 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1990 | 1968 | 0.020 |
Why?
| | Glucocorticoids | 1 | 1990 | 570 | 0.020 |
Why?
| | Retinol-Binding Proteins | 1 | 2005 | 14 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2010 | 533 | 0.020 |
Why?
| | Adipose Tissue | 1 | 1990 | 588 | 0.020 |
Why?
| | Skin Physiological Phenomena | 1 | 1985 | 25 | 0.020 |
Why?
| | Diterpenes | 1 | 2005 | 32 | 0.020 |
Why?
| | Cause of Death | 1 | 2007 | 392 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2006 | 539 | 0.020 |
Why?
| | Amylopectin | 1 | 2005 | 5 | 0.020 |
Why?
| | Esterification | 1 | 2005 | 11 | 0.020 |
Why?
| | Electrodes | 1 | 1985 | 103 | 0.020 |
Why?
| | Dry Eye Syndromes | 1 | 2005 | 36 | 0.020 |
Why?
| | Reoperation | 1 | 2007 | 555 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 2005 | 166 | 0.010 |
Why?
| | Viral Load | 1 | 2006 | 448 | 0.010 |
Why?
| | Oxygen Consumption | 2 | 2002 | 676 | 0.010 |
Why?
| | Leukocytes, Mononuclear | 1 | 2006 | 543 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2003 | 18 | 0.010 |
Why?
| | Needs Assessment | 1 | 2006 | 360 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 2003 | 63 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 265 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2003 | 126 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2003 | 194 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 783 | 0.010 |
Why?
| | Surgical Procedures, Operative | 1 | 1985 | 249 | 0.010 |
Why?
| | Splenomegaly | 1 | 2002 | 16 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1070 | 0.010 |
Why?
| | Ornithine | 1 | 2002 | 24 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 417 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 602 | 0.010 |
Why?
| | Medical Records | 1 | 2002 | 170 | 0.010 |
Why?
| | Glutamine | 1 | 2002 | 94 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2005 | 387 | 0.010 |
Why?
| | Influenza Vaccines | 1 | 2006 | 544 | 0.010 |
Why?
| | Alanine | 1 | 2002 | 134 | 0.010 |
Why?
| | Cardiac Catheterization | 1 | 2005 | 583 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 822 | 0.010 |
Why?
| | Vaccination | 1 | 2009 | 1350 | 0.010 |
Why?
| | Arginine | 1 | 2002 | 254 | 0.010 |
Why?
| | Parents | 1 | 2009 | 1301 | 0.010 |
Why?
| | DNA Probes | 2 | 1990 | 61 | 0.010 |
Why?
| | Fibroblasts | 1 | 2005 | 946 | 0.010 |
Why?
| | gamma-Globulins | 1 | 1998 | 18 | 0.010 |
Why?
| | Jaundice | 1 | 1998 | 14 | 0.010 |
Why?
| | Esophagoscopes | 1 | 1996 | 4 | 0.010 |
Why?
| | Endoscopes | 1 | 1996 | 18 | 0.010 |
Why?
| | Ligation | 1 | 1996 | 87 | 0.010 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1995 | 26 | 0.010 |
Why?
| | Ulcer | 1 | 1995 | 28 | 0.010 |
Why?
| | Microsomes, Liver | 1 | 1994 | 64 | 0.010 |
Why?
| | Necrosis | 1 | 1995 | 234 | 0.010 |
Why?
| | Azathioprine | 1 | 1994 | 48 | 0.010 |
Why?
| | Diarrhea | 1 | 1995 | 179 | 0.010 |
Why?
| | Drug Resistance | 1 | 1994 | 166 | 0.010 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 1998 | 379 | 0.010 |
Why?
| | Fever | 1 | 1995 | 301 | 0.010 |
Why?
| | Dogs | 1 | 1994 | 372 | 0.010 |
Why?
| | Length of Stay | 1 | 1998 | 1126 | 0.010 |
Why?
| | Linear Models | 1 | 1995 | 817 | 0.010 |
Why?
| | Acetaminophen | 1 | 1995 | 255 | 0.010 |
Why?
| | Regression Analysis | 1 | 1994 | 987 | 0.010 |
Why?
| | Blood Glucose | 1 | 2002 | 2086 | 0.010 |
Why?
| | Pancreatin | 1 | 1991 | 5 | 0.010 |
Why?
| | Taurocholic Acid | 1 | 1990 | 33 | 0.010 |
Why?
| | Biological Transport, Active | 1 | 1990 | 72 | 0.010 |
Why?
| | Hydroxycholecalciferols | 1 | 1989 | 3 | 0.010 |
Why?
| | Infant Nutrition Disorders | 1 | 1989 | 11 | 0.010 |
Why?
| | Vitamin K | 1 | 1989 | 42 | 0.010 |
Why?
| | Cell Survival | 1 | 1990 | 1082 | 0.000 |
Why?
| | Energy Intake | 1 | 1990 | 453 | 0.000 |
Why?
| | Iridium | 1 | 1985 | 7 | 0.000 |
Why?
| | Partial Pressure | 1 | 1985 | 29 | 0.000 |
Why?
| | Skin Temperature | 1 | 1985 | 31 | 0.000 |
Why?
| | Colorado | 1 | 1995 | 4443 | 0.000 |
Why?
| | Aged | 2 | 1994 | 22035 | 0.000 |
Why?
|
|
Narkewicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|